Nanocurcumin: A novel strategy in treating ankylosing spondylitis by modulating Th17 cells frequency and function
Nanocurcumin: A novel strategy in treating ankylosing spondylitis by modulating Th17 cells frequency and function
نویسندگان: مهرزاد حاج علیلوی بناب , صنم دولتی , سمانه عبدالمحمدی وحید , مجید احمدی , امین کامرانی , شادی اقبال فرد , آرزو قاسم بگلو , امیر ولیزاده دیزجیکان , محمد حسین موسوی شناس , لیلی عاقبتی , امیر مهدی زاده حقیقی , حسین صمدی کفیل , مهدی یوسفی
کلمات کلیدی:
نشریه: 19611 , 2019 , 120 , 2019
| نویسنده ثبت کننده مقاله |
مهدی یوسفی |
| مرحله جاری مقاله |
تایید نهایی |
| دانشکده/مرکز مربوطه |
مرکز تحقیقات کاربردی دارویی |
| کد مقاله |
66875 |
| عنوان فارسی مقاله |
Nanocurcumin: A novel strategy in treating ankylosing spondylitis by modulating Th17 cells frequency and function |
| عنوان لاتین مقاله |
Nanocurcumin: A novel strategy in treating ankylosing spondylitis by modulating Th17 cells frequency and function |
| ناشر |
13 |
| آیا مقاله از طرح تحقیقاتی و یا منتورشیپ استخراج شده است؟ |
بلی |
| عنوان نشریه (خارج از لیست فوق) |
|
| نوع مقاله |
Original Article |
| نحوه ایندکس شدن مقاله |
ایندکس شده سطح یک – ISI - Web of Science |
| آدرس لینک مقاله/ همایش در شبکه اینترنت |
|
| Ankylosing spondylitis (AS) is a chronic rheumatic disease which mainly affects the
axial skeleton and sacroiliac joints. T‐helper 17 (Th17) cells have been reportedly
involved in AS pathogenesis. Nanocurcumin is considered to be beneficial, as an
anti‐inflammatory compound, in AS patients treatment. In this study, Th17‐related
immunological parameters were evaluated in AS patients. Transcription factors
messenger RNA (mRNA) expression level, cytokines, and related microRNAs
(miRNAs) were measured by real‐time polymerase chain reaction. Additionally,
Th17 frequency and cytokines secretion were evaluated by flow cytometry and
enzyme‐linked immunosorbent assay tests, respectively. The frequency of Th17 was
higher in AS patients. Gained data from nanocurcumin group also demonstrated
that retinoic acid‐related orphan receptor γ (RORγt) and interleukin‐17 (IL‐17)
mRNA expression levels were significantly decreased (P=0.0001 and 0.0006,
respectively), as the decrease also happened in Th17‐associated miRNAs including
miR‐141, miR‐155, and miR‐200 (P= 0.04, P=0.02, and P < 0.0001, respectively).
Posttreatment data of miR‐155 and miR‐200 in the nanocurcumin and placebo
groups also showed a higher expression level in the placebo group compared with
nanocurcumin‐treated patients. Some clinical symptoms of AS patients were also
improved at the end of the treatment process. The results of this study showed the
potential ability of nanocurcumin to regulate Th17 cells activity in AS patients. This
study provided further evidence on the function and underlying mechanism of
nanocurcumin helping better treatment of AS. |
| نام فایل |
تاریخ درج فایل |
اندازه فایل |
دانلود |
| Nanocurcumin, ankylosing.pdf | 1398/02/27 | 952897 | دانلود |